DOK4 Antibody

What is DOK4 and what are its primary biological functions?

DOK4 (Docking Protein 4) is a member of the INS-receptor substrate family that plays important roles in cellular growth, signaling, and survival. Also known as downstream of tyrosine kinase 4 or insulin receptor substrate 5 (IRS-5), DOK4 functions as an enzymatically inert adaptor or scaffolding protein that provides a docking platform for the assembly of multimolecular signaling complexes . It plays critical roles in RET-mediated neurite outgrowth during neuronal development through activation of the Rap1-ERK1/2 pathway . DOK4 is required at early stages in the myelination process, including the initial interaction with axons, and is also involved in Schwann cell migration and proliferation . Additionally, it may function as a negative regulator of T cells, similar to other DOK family members like DOK1 and DOK2 .

What are the key specifications of commercially available DOK4 antibodies?

DOK4 antibodies are predominantly available as rabbit polyclonal antibodies targeting various epitopes of the protein . These antibodies typically detect DOK4 at its observed molecular weight of 37 kDa, which aligns with its calculated molecular weight . They are generally supplied in liquid form, in PBS buffer containing 50% glycerol and 0.02% sodium azide, with a pH of approximately 7.3-7.4 . Most commercial antibodies have undergone antigen affinity purification and demonstrate reactivity against human, mouse, and rat samples . Some antibodies exhibit broader reactivity across multiple species including cow, dog, guinea pig, and others .

What is the tissue distribution pattern of DOK4 protein?

DOK4 exhibits a wide tissue distribution pattern with notable expression differences:

DOK4 is expressed in both resting and activated peripheral blood T-cells, suggesting its potential role in immune function regulation . Understanding this tissue distribution pattern is crucial for selecting appropriate positive control tissues when validating DOK4 antibodies for specific applications.

What applications are DOK4 antibodies validated for?

DOK4 antibodies have been validated for multiple applications in protein research:

Researchers should note that optimal dilutions may vary depending on the specific experimental conditions, sample types, and detection methods employed . It is recommended to titrate the antibody in each testing system to obtain optimal results .

How can I design experiments to investigate DOK4's role in the MAP kinase pathway using available antibodies?

To effectively investigate DOK4's role in the MAP kinase pathway, design experiments that combine antibody-based detection with functional assays. Start by establishing baseline DOK4 expression in your experimental model using validated antibodies via Western blotting (1:500-1:1000 dilution) . Then implement a multi-faceted approach: (1) Conduct co-immunoprecipitation experiments using anti-DOK4 antibodies to identify binding partners in the MAP kinase cascade; (2) Perform phosphorylation state analysis using phospho-specific antibodies alongside DOK4 detection following stimulation with RET ligands like GDNF; (3) Utilize immunofluorescence (1:200-1:1000 dilution) to track DOK4 subcellular localization before and after pathway activation . For functional validation, implement DOK4 knockdown or overexpression systems and assess effects on ERK1/2 phosphorylation states. When analyzing data, remember that DOK4 functions as a positive regulator of MAP kinase pathway activation, particularly in neuronal differentiation contexts .

How can I resolve contradictory findings when antibodies detect different molecular weights for DOK4?

When antibodies detect DOK4 at molecular weights that differ from the expected 37 kDa , implement a systematic troubleshooting approach. First, validate your findings by running parallel Western blots using multiple anti-DOK4 antibodies targeting different epitopes (N-terminal versus C-terminal regions) . Include appropriate positive controls such as skeletal muscle tissue extracts where DOK4 is highly expressed . Consider that post-translational modifications, particularly phosphorylation in response to insulin, IGF1, or RET stimulation , can alter electrophoretic mobility. To investigate potential splice variants, design PCR primers spanning different exon junctions and perform RT-PCR analysis alongside protein detection. For suspected proteolytic fragments, include protease inhibitors during sample preparation and test fresh versus frozen samples. If cross-reactivity is suspected, perform peptide competition assays using the immunizing peptide. For definitive identification, consider immunoprecipitation followed by mass spectrometry analysis. Document all experimental conditions carefully, as buffer compositions, reducing agents, and gel percentages can significantly impact observed molecular weights. Contradictory findings often reflect biological complexity rather than technical errors and may reveal important insights about DOK4 regulation in your specific experimental system.

What are the most effective approaches for studying DOK4's interactions with the RET signaling pathway using antibodies?

To effectively study DOK4's interactions with the RET signaling pathway, employ a multi-method approach centered on spatial, temporal, and functional analyses. Begin with co-immunoprecipitation experiments using anti-DOK4 antibodies (affinity-purified, 1:500 dilution for western verification) to pull down RET and associated signaling components from neuronal cells. For temporal dynamics, conduct time-course experiments following GDNF stimulation, simultaneously assessing DOK4 phosphorylation status and its association with RET. Implement proximity ligation assays to visualize DOK4-RET interactions in situ with high sensitivity. For functional studies, compare neurite outgrowth in control versus DOK4-depleted neuronal cultures treated with GDNF, quantifying both morphological parameters and downstream ERK1/2 activation . Use immunofluorescence (1:200-1:1000 dilution) to examine subcellular co-localization of DOK4 with RET at membrane microdomains during neurite extension . When analyzing specific binding mechanisms, focus on the PTB domain of DOK4, which mediates receptor interactions . Remember that DOK4 functions as a scaffolding protein in this context, facilitating the assembly of multimolecular signaling complexes that connect RET activation to neurite outgrowth through the Rap1-ERK1/2 signaling axis .

How should I select the optimal DOK4 antibody for my specific research application?

Selecting the optimal DOK4 antibody requires careful consideration of multiple factors specific to your experimental goals. Begin by clarifying whether your research focuses on a particular domain of DOK4 or requires total protein detection. For domain-specific studies, choose antibodies targeting relevant epitopes—N-terminal antibodies for membrane-proximal interactions or C-terminal antibodies for downstream signaling events . Review the antibody's validated applications and match them to your intended methodology—Western blotting (1:500-1:1000), immunohistochemistry (1:100-1:300), or immunofluorescence (1:200-1:1000) . Verify species reactivity aligns with your experimental model; while most DOK4 antibodies react with human, mouse, and rat samples, specific applications might require broader reactivity . For phosphorylation studies, specifically select phospho-DOK4 antibodies. Check the antibody's validation profile including published literature citations, manufacturer's validation data, and molecular weight confirmation (37 kDa for DOK4) . For complex tissue samples like skeletal muscle or brain, where DOK4 expression varies significantly, prioritize antibodies with documented specificity in these tissues . Finally, consider the antibody's formulation compatibility with your experimental conditions, particularly for live-cell applications where sodium azide in storage buffers may be problematic .

What are the essential controls for validating DOK4 antibody specificity in experimental systems?

Comprehensive validation of DOK4 antibody specificity requires implementing multiple complementary controls. First, include positive tissue controls with known high DOK4 expression (skeletal muscle, heart, kidney, and liver) alongside tissues with lower expression (spleen, lung) to verify signal gradient correlation with established expression patterns. For negative controls, use DOK4 knockout cell lines or tissues generated through CRISPR-Cas9 technology, or alternatively, implement siRNA-mediated DOK4 knockdown systems to demonstrate signal reduction. Perform peptide competition assays using the immunizing peptide (such as DOK4 fusion protein Ag0734 or synthetic peptides from specific regions like AA 11-60) to confirm signal displacement. Include isotype controls matching the DOK4 antibody host species and immunoglobulin class to identify non-specific binding. For Western blotting applications, run parallel blots with multiple DOK4 antibodies targeting different epitopes to confirm consistent detection at 37 kDa . In immunostaining applications, evaluate subcellular localization patterns against known DOK4 distribution. For definitive validation in challenging contexts, consider orthogonal detection methods such as mass spectrometry following immunoprecipitation or correlation with mRNA expression via RT-PCR. Document all validation experiments thoroughly, including antibody dilution, incubation conditions, and detection systems, to establish reproducible protocols for subsequent experiments.

How can I optimize western blot protocols for detecting low-abundance DOK4 in non-muscle tissues?

Optimizing western blot protocols for low-abundance DOK4 detection in tissues like spleen, lung, or brain requires several key modifications. Begin with sample preparation enhancements: increase protein loading (50-80 μg total protein), use phosphatase inhibitors to preserve all DOK4 phosphorylation states, and employ gentler lysis buffers containing 1% NP-40 or Triton X-100 rather than harsh detergents. For enrichment, consider implementing immunoprecipitation prior to Western blotting to concentrate DOK4 protein. During electrophoresis, use gradient gels (4-15%) and extend transfer times to 16 hours at lower voltage (30V) in cold room conditions to improve transfer efficiency of the 37 kDa DOK4 protein . For antibody incubation, reduce the dilution factor toward the lower end of the recommended range (1:500 rather than 1:1000) , extend primary antibody incubation to overnight at 4°C, and use high-sensitivity detection systems such as HRP-conjugated secondaries combined with enhanced chemiluminescent substrates with femtogram sensitivity. Signal amplification can be achieved using biotinylated secondary antibodies with streptavidin-HRP. Implement longer exposure times (up to 10-15 minutes) during imaging, and consider using digital imaging systems with cumulative exposure functions. For tissues with autofluorescence concerns, chemiluminescent detection is preferable over fluorescent secondaries. Always run positive controls (skeletal muscle extracts) alongside experimental samples to confirm proper technique and antibody functionality .

What are the critical steps to achieve specific DOK4 immunofluorescence staining in neural tissues?

Achieving specific DOK4 immunofluorescence staining in neural tissues requires careful attention to several critical steps. Begin with optimized fixation—use 4% paraformaldehyde for 15-20 minutes, as overfixation can mask DOK4 epitopes while underfixation compromises structural integrity. For antigen retrieval, implement citrate buffer (pH 6.0) heating at 95°C for 15-20 minutes, followed by a slow cool-down to enhance epitope accessibility without damaging neural architecture. Block thoroughly with 5-10% normal serum from the secondary antibody's host species, supplemented with 0.3% Triton X-100 for membrane permeabilization and 1% BSA to reduce non-specific binding . Dilute primary DOK4 antibodies at 1:200-1:400 for neural tissues (more concentrated than the 1:1000 upper range) and incubate for 24-48 hours at 4°C to allow sufficient penetration into complex neural structures. Include co-staining with established neural markers (NeuN, GFAP, neurofilament) to provide cellular context for DOK4 localization. For secondary antibody incubation, use highly cross-adsorbed antibodies to prevent non-specific binding and extend incubation to 2 hours at room temperature. Incorporate DAPI nuclear counterstain at a final step. When imaging, acquire Z-stack series to capture DOK4 distribution throughout the tissue depth, and include no-primary-antibody controls processed in parallel to distinguish true signal from background autofluorescence, which is particularly problematic in neural tissues . Compare staining patterns with the known DOK4 distribution in neuronal development and myelination processes to verify biological relevance .

How should I design experiments to investigate the phosphorylation dynamics of DOK4 following stimulus exposure?

Designing experiments to investigate DOK4 phosphorylation dynamics requires a carefully structured approach combining temporal resolution, phosphorylation-specific detection, and functional correlation. First, establish appropriate cell models expressing detectable DOK4 levels (neuronal lines, skeletal muscle cells, or T cells) and verify baseline expression using standard DOK4 antibodies (1:500-1:1000 dilution) . Design a time-course experiment with short intervals (0, 2, 5, 10, 15, 30, 60 minutes) following stimulation with known DOK4-activating factors such as insulin, IGF-1, or GDNF . During cell lysis, use buffers containing strong phosphatase inhibitor cocktails (including sodium orthovanadate and sodium fluoride) and maintain samples at 4°C throughout processing to preserve phosphorylation states. For detection, implement dual strategies: (1) use phospho-tyrosine antibodies for immunoprecipitation of DOK4 followed by DOK4 antibody detection, and (2) directly probe blots with phospho-DOK4 antibodies if available. Include parallel blots for total DOK4 to calculate phosphorylation-to-total protein ratios. For functional correlation, simultaneously assess activation of downstream effectors in the Rap1-ERK1/2 pathway across the same time points. Implement inhibitor studies (tyrosine kinase inhibitors specific to relevant pathways) to verify phosphorylation mechanisms. For confirmation, conduct mass spectrometry analysis of immunoprecipitated DOK4 to identify specific phosphorylation sites and their dynamics. When analyzing results, normalize phosphorylation signals to total DOK4 levels and correlate temporal patterns with downstream pathway activation to establish causal relationships in signaling cascades.

How can I distinguish between DOK4 and other DOK family members in experimental data?

Distinguishing between DOK4 and other DOK family members requires implementation of multiple complementary approaches to ensure specificity in protein detection. Start by selecting antibodies that target unique regions of DOK4 not conserved across the DOK family—particularly the regions outside the highly conserved IRS-type PTB domain . Verify the antibody's specificity through Western blotting against recombinant DOK1-7 proteins expressed in a controlled system. When analyzing experimental data, note that DOK4 appears at 37 kDa while other family members have distinct molecular weights (e.g., DOK1 at 62 kDa, DOK2 at 56 kDa) . For immunostaining applications, leverage the unique tissue distribution patterns—DOK4 shows high expression in skeletal muscle, heart, kidney, and liver, creating a signature pattern distinct from other DOK proteins . In functional studies, design experiments around DOK4-specific interactions, particularly its role in RET-mediated neurite outgrowth and Rap1-ERK1/2 pathway activation . For gene expression analysis, design PCR primers that target unique exon junctions specific to DOK4. When interpreting experimental results showing potential family member overlap, implement siRNA knockdown with DOK4-specific sequences to confirm signal attribution. Remember that DOK4 (also called IRS5) has functional characteristics that partially overlap with insulin receptor substrates while maintaining distinct roles in neuronal development that other DOK family members do not share . These combined approaches allow confident discrimination between DOK4 and related family proteins in complex experimental contexts.

What approaches should I use to quantitatively analyze DOK4 expression levels across different tissue samples?

Quantitative analysis of DOK4 expression across diverse tissue samples requires a methodical approach that addresses tissue-specific challenges while ensuring reproducible measurements. For Western blot quantification, implement a standardized protocol using identical protein loading amounts (30-50 μg) verified through total protein stains (REVERT or Ponceau S) . Use internal loading controls appropriate for each tissue type—GAPDH may be unsuitable across tissues with varying metabolic activities, so consider structural proteins like β-actin or α-tubulin, or preferably, total protein normalization. When processing Western blot images, use software that measures integrated density values within linear detection ranges, avoiding saturated signals. For cross-tissue comparisons, include a common reference sample (e.g., pooled tissue lysate) on each blot to allow inter-blot normalization. For immunohistochemical quantification of DOK4, employ standardized staining protocols (1:100-1:300 dilution) across all samples processed simultaneously, and use automated image analysis algorithms that segment tissue regions consistently. Implement rigorous statistical analysis—report data as mean ± standard deviation from at least three biological replicates, and apply appropriate statistical tests (ANOVA with post-hoc tests for multi-tissue comparisons). For absolute quantification, consider developing a standard curve using recombinant DOK4 protein. When interpreting results, contextualize findings against known DOK4 distribution patterns, with expectation of higher signals in skeletal muscle, heart, kidney, and liver compared to spleen, lung, and small intestine . This comprehensive approach ensures reliable quantitative comparisons of DOK4 expression that reflect true biological differences rather than technical variations.

How should I interpret DOK4 localization patterns in different cellular contexts?

Interpreting DOK4 localization patterns across cellular contexts requires careful consideration of its adaptor protein function and context-dependent interactions. When analyzing immunofluorescence or immunohistochemistry results (obtained using 1:100-1:300 dilutions) , expect to observe distinct localization patterns that correlate with cellular function. In neuronal cells, DOK4 typically exhibits enrichment at growth cones and developing neurites, consistent with its role in GDNF-mediated neurite outgrowth via Rap1-ERK1/2 pathway activation . In Schwann cells, look for DOK4 concentration at axonal contact sites during early myelination phases . For muscle cells, DOK4 distribution should correlate with regions of high metabolic activity and insulin signaling. In T cells, where DOK4 may function as a negative regulator , analyze its redistribution following T cell receptor engagement. When performing co-localization studies, select markers that highlight relevant subcellular compartments—membrane markers for regions of receptor engagement, cytoskeletal components for structural associations, and signaling pathway components like activated ERK1/2 for functional correlations. Use super-resolution microscopy techniques when possible to distinguish membrane-proximal versus cytoplasmic distributions. For dynamic processes, implement live-cell imaging using fluorescently-tagged DOK4 constructs to track redistribution following stimuli like insulin, IGF-1, or GDNF . When interpreting altered localization patterns in experimental models, consider both the adaptor function of DOK4 (requiring proximity to interaction partners) and its PTB domain-mediated receptor interactions . Changes in localization often precede and facilitate downstream signaling events, making spatial analysis a powerful tool for understanding DOK4's functional roles across different cell types.

What strategies can I employ to investigate DOK4's role in T-cell regulation using available antibodies?

Investigating DOK4's role in T-cell regulation requires a comprehensive experimental approach leveraging antibodies for both detection and functional analysis. Begin by establishing baseline DOK4 expression in resting versus activated T-cell populations using Western blotting (1:500-1:1000 dilution) , noting that DOK4 is expressed in both states . For mechanistic studies, use immunoprecipitation with DOK4 antibodies to identify binding partners in T-cell signaling pathways, particularly focusing on interactions that might explain its proposed negative regulatory function similar to DOK1 and DOK2 . Implement phospho-specific analyses to track DOK4 phosphorylation status following T-cell receptor engagement, co-stimulation, and cytokine exposure, using strong phosphatase inhibitors during sample preparation. For spatial studies, use immunofluorescence (1:200-1:400 dilution) to track DOK4 redistribution during immunological synapse formation . Design functional experiments comparing wild-type T-cells with DOK4-depleted (siRNA) or DOK4-overexpressing T-cells, analyzing proliferation rates, cytokine production, and activation marker expression. For in vivo relevance, examine DOK4 expression in T-cell populations from different immune contexts (naïve, effector, memory, exhausted) using flow cytometry with intracellular DOK4 staining. When analyzing results, remember to differentiate DOK4's roles from other DOK family members, which may have overlapping but distinct functions in T-cell biology. This multi-faceted approach will help establish whether DOK4 functions primarily as a negative regulator in T-cells as suggested by its relationship to DOK1 and DOK2 , or if it has context-dependent functions in different T-cell subsets or activation states.